Guided Therapeutics (GTHP) Share-based Compensation Growth (3y) (2014 - 2026)
Guided Therapeutics (GTHP) Share-based Compensation Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 8.37% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | -28.31% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 8.20% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 13.19% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 4.11% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -0.59% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 17.13% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 36.49% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 3.40% |
| 10 | Guided Therapeutics | 21.24 Mn | 21.23 Mn | - | -44.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.43% |
| Dec 31, 2025 | -59.77% |
| Sep 30, 2025 | -29.96% |
| Jun 30, 2025 | 44.02% |
| Mar 31, 2025 | -92.44% |
| Dec 31, 2024 | -29.73% |
| Sep 30, 2024 | -33.94% |
| Jun 30, 2024 | -35.10% |
| Mar 31, 2024 | -92.15% |
| Dec 31, 2023 | -42.88% |
| Sep 30, 2023 | -59.09% |
| Sep 30, 2022 | 144.78% |
| Mar 31, 2022 | 106.46% |
| Dec 31, 2021 | 99.07% |
| Sep 30, 2021 | 58.74% |
| Jun 30, 2021 | 37.66% |
| Mar 31, 2021 | 68.33% |
| Dec 31, 2020 | 169.78% |
| Sep 30, 2020 | 67.93% |
| Sep 30, 2019 | -45.95% |